Women's Health
Peptides for Women: BPC-157, TB-500, GHK-Cu & PT-141
Four peptides that women use for recovery, skin health, hair, and libido -- with the actual research behind each one, correct dosing, and what to avoid during pregnancy.
TL;DR -- GHK-Cu tops the list for skin and hair. BPC-157 handles gut, joint, and tissue repair. TB-500 covers systemic recovery. PT-141 (bremelanotide) is FDA-approved for female sexual dysfunction. Dosing for women matches men except PT-141, which is used at lower doses.
Calculate Your Dose
Pick a peptide to start
Each peptide has a dedicated calculator for reconstitution math and dosing.
BPC-157
BPC-157 for Women: Gut, Joints & Pelvic Tissue
BPC-157 is a 15-amino-acid peptide derived from a gastric protein. It promotes healing through multiple signaling pathways -- upregulating growth factor receptors, modulating nitric oxide, and accelerating blood vessel formation in damaged tissue.
For women, the most studied use cases are gut lining repair, joint and tendon healing, and inflammation reduction. A body of rodent studies shows benefit in colitis models, tendon transection, and ligament injury. Human use follows the same dosing as men.
Gut healing. BPC-157 reduces intestinal permeability, promotes mucosal repair, and modulates gut motility. Women with IBS, IBD, or post-antibiotic gut disruption report the strongest subjective response.
Pelvic floor inflammation. Animal data suggests anti-inflammatory action in smooth muscle and connective tissue. This has generated interest for women dealing with pelvic floor strain, overactive bladder, or endometriosis-related tissue inflammation. No controlled human data exists yet.
Joint and tendon repair. Multiple rodent studies show accelerated healing of tendon-to-bone insertions and ligament tears. Useful for active women dealing with repetitive strain, knee ligament laxity, or post-surgical recovery.
Endometriosis pain (animal data). A small body of animal research suggests BPC-157 may reduce inflammation in ectopic endometrial tissue. This is speculative at the human level but is an area of active user interest.
Dosing: 200--500 mcg per day, subcutaneous injection near the site of injury or abdominal injection for gut issues. Oral capsule form also used for GI-specific effects at 500 mcg -- 1 mg/day. No dose adjustment for women vs. men.
Pregnancy warning: Avoid BPC-157 during pregnancy. BPC-157 promotes angiogenesis (new blood vessel formation). No safety data exists for fetal development. Discontinue at least 4 weeks before attempting conception.
TB-500
TB-500: Systemic Recovery for Active Women
TB-500 is a synthetic version of Thymosin Beta-4, a peptide naturally produced in high concentrations at sites of tissue injury. Its primary mechanism is actin regulation -- it sequesters G-actin, enabling faster cell migration into damaged areas and promoting connective tissue remodeling.
Unlike BPC-157, which is best used locally or gut-targeted, TB-500 is a systemic healing peptide. It circulates and works throughout the body. This makes it well-suited for diffuse connective tissue issues rather than single-site injuries.
Ligament and tendon repair. TB-500 consistently outperforms controls in animal tendon repair studies. Women dealing with chronic ligament laxity, hypermobility, or repetitive strain injuries use it for longer protocol runs of 4--8 weeks.
Postpartum connective tissue recovery. Pregnancy stretches and alters abdominal fascia, pelvic ligaments, and symphysis pubis. TB-500's systemic connective tissue repair action has made it a point of interest for women dealing with diastasis recti and pelvic girdle pain postpartum. No clinical trial data exists for this application.
Anti-inflammatory systemic effect. TB-500 reduces inflammatory cytokine signaling in damaged tissue, which can accelerate return to training after high-load exercise or injury.
Cardiac and smooth muscle healing. Animal data shows TB-500 reduces scar formation after cardiac injury and supports smooth muscle remodeling. Interest area for women with connective tissue disorders (Ehlers-Danlos, Marfan).
Dosing: Loading phase 2--2.5 mg twice weekly for 4--6 weeks, then maintenance 2 mg every 2 weeks. Subcutaneous injection. Same dosing used for men and women.
Pregnancy and breastfeeding: No safety data exists. TB-500 promotes tissue remodeling via pathways that are active in fetal development. Avoid during pregnancy and breastfeeding.
GHK-Cu
GHK-Cu: The Most Popular Peptide Among Women
GHK-Cu (glycine-histidine-lysine copper peptide) is the most widely used peptide in women's health. It is found naturally in plasma, saliva, and urine, and declines sharply after age 60. Its primary roles are collagen synthesis stimulation, antioxidant gene activation, and wound repair signaling.
What makes GHK-Cu unique is that it works both topically and systemically -- and topical use is backed by multiple clinical studies, not just animal data.
Collagen and elastin synthesis. GHK-Cu directly activates collagen I, III, and IV production along with elastin and proteoglycans. In clinical studies, topical application for 12 weeks measurably reduced wrinkle depth and improved skin density compared to placebo.
Skin elasticity and hydration. GHK-Cu upregulates aquaporin channels in skin cells and activates fibroblast activity. Results are more pronounced in women over 35 where baseline collagen production has declined.
Hair growth. GHK-Cu increases the size of hair follicle cells and prolongs the anagen (growth) phase. Topical scalp application is comparable in some studies to minoxidil for diffuse thinning. Systemic injection may provide a broader follicular signal.
Wound healing and scar reduction. GHK-Cu reduces transforming growth factor-beta (TGF-b) activity at wound sites, shifting repair from scar formation toward organized collagen deposition. Used topically on surgical or acne scars.
T
Topical use: Apply GHK-Cu serum or cream (typically 0.5--2% concentration) once or twice daily to face, neck, or scalp. Avoid mixing with high-strength vitamin C or AHA/BHA acids on the same application -- pH conflict degrades copper peptides.
S
Systemic use: 1--2 mg per day subcutaneous injection. Often run 5 days on, 2 days off. Some protocols use 1 mg every other day for maintenance. Systemic dosing is reported to produce stronger hair and nail effects than topical alone.
No pregnancy contraindication known, but systemic injections during pregnancy lack safety data. Topical GHK-Cu in cosmetic concentrations (less than 2%) is generally considered low-risk. Consult a provider before systemic use during pregnancy.
PT-141
PT-141: The Only FDA-Approved Peptide for Female Sexual Dysfunction
PT-141 (bremelanotide) is unique in this group: it is FDA-approved. The FDA cleared it in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works by activating melanocortin MC3R and MC4R receptors in the hypothalamus -- a central arousal pathway that is entirely independent of hormones or blood flow.
This central mechanism is why PT-141 works for women whose low libido is not explained by low estrogen or testosterone. It addresses the desire signal itself, not the downstream physiology.
FDA-approved indication. Vyleesi (bremelanotide 1.75 mg) is indicated for HSDD in premenopausal women. Clinical trials showed a statistically significant increase in satisfying sexual events and a reduction in distress related to low desire vs. placebo.
Mechanism. Melanocortin activation in the hypothalamus increases dopamine release and activates circuits associated with sexual motivation. Unlike sildenafil (Viagra), it does not affect genital blood flow directly -- the arousal effect comes from the brain.
Use as needed. PT-141 is dosed before anticipated sexual activity, not daily. Onset is 30--60 minutes. Duration of effect is 4--8 hours. No need to time it to a partner's schedule like daily hormonal approaches.
Dosing for women -- lower than men: The FDA-approved dose is 1.75 mg subcutaneous. Research peptide protocols frequently use 0.5--1.0 mg to reduce side effects (flushing, nausea, transient blood pressure increase). Start at 0.5 mg and titrate up. Men typically use 1.0--2.0 mg; women respond at lower doses due to higher central MC4R sensitivity.
Side effects to know: Transient facial flushing (most common), nausea (dose-dependent, much less at 0.5 mg), and a brief blood pressure increase of 2--4 mmHg lasting 4--12 hours. Do not use with cardiovascular disease or within 24 hours of erectile dysfunction drugs.
Avoid during pregnancy. PT-141 activates central melanocortin receptors that are involved in fetal development signaling. Contraindicated during pregnancy and when trying to conceive.
Peptide Comparison
Quick Reference: Women's Peptide Dosing
| Peptide | Primary Use | Dose (Women) | Status |
|---|---|---|---|
| BPC-157 | Gut, joints, tissue repair | 200--500 mcg/day SubQ | Research |
| TB-500 | Systemic recovery, tendons | 2--2.5 mg 2x/week (load) | Research |
| GHK-Cu | Skin, collagen, hair | 1--2 mg/day SubQ or topical | Research |
| PT-141 | Libido, sexual desire | 0.5--1.75 mg as needed | FDA Approved |
Women's Wellness Stack
GHK-Cu + BPC-157 + PT-141 Stack
These three peptides cover distinct mechanisms with no known adverse interactions. Together they address the most common reasons women explore peptide research: appearance, recovery, and desire.
Women's Wellness Stack -- Core Three
GHK-Cu
Skin elasticity, collagen, hair growth
1--2 mg/day
BPC-157
Gut lining, pelvic tissue, joint repair
250--500 mcg/day
PT-141
Central arousal, libido, desire
0.5--1.0 mg as needed
Stack tip: Run GHK-Cu and BPC-157 daily for 8--12 weeks for tissue and skin effects. Use PT-141 only as needed -- it is not a daily peptide and tolerance builds with frequent use. Space PT-141 doses at least 72 hours apart for best response.
TB-500 as an add-on: Add TB-500 to the stack when the primary goal is systemic connective tissue recovery -- for example, after surgery, postpartum, or managing a chronic injury. Run it as a separate loading protocol rather than daily alongside BPC-157.
Pregnancy & Safety
What to Avoid and When
None of these peptides have controlled safety data in human pregnancy. The mechanisms that make them effective for tissue repair and signaling are also active in fetal development, which creates theoretical risk.
BPC-157 -- avoid during pregnancy. Pro-angiogenic effects (promotes new blood vessel formation) may interfere with normal placental vascular development. Discontinue at least 4 weeks before attempting to conceive.
TB-500 -- avoid during pregnancy and breastfeeding. Thymosin Beta-4 plays a role in fetal organ development. No safety data exists for pregnant or lactating women.
PT-141 -- contraindicated in pregnancy. The FDA label explicitly lists pregnancy as a contraindication. Central melanocortin activation during fetal development carries unknown but theoretical risk.
GHK-Cu systemic -- use caution. Topical cosmetic use is considered low-risk. Systemic injection during pregnancy lacks safety data. Conservative approach is to pause systemic GHK-Cu while pregnant or attempting conception.
Timing rule: If planning pregnancy, stop all research peptide protocols at least 4--6 weeks before attempting conception. Confirm with your OB before resuming postpartum, especially while breastfeeding.
FAQ
Common Questions
Is BPC-157 safe for women?
BPC-157 has a strong safety profile in rodent studies with no significant adverse effects reported. Women use the same dosing as men -- typically 200--500 mcg per day injected subcutaneously. Avoid during pregnancy as no human safety data exists for that period. No hormone interaction has been reported in animal studies.
What does GHK-Cu do for women's skin?
GHK-Cu stimulates collagen and elastin synthesis, activates antioxidant systems, and promotes skin repair. Studies show it reduces fine lines, improves skin density, and accelerates wound healing. It works both topically (in skincare products and serums at 0.5--2%) and systemically via injection at 1--2 mg per day.
Is PT-141 FDA approved for women?
Yes. PT-141 (bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. The approved dose is 1.75 mg subcutaneous before sexual activity. Research peptide protocols typically use 0.5--1.0 mg to reduce side effects like flushing and nausea.
Can women use TB-500 for postpartum recovery?
TB-500 promotes systemic tissue repair and connective tissue remodeling -- properties relevant to postpartum recovery of the pelvic floor and abdominal fascia. However, there is no controlled human data for this use. Avoid during breastfeeding as safety data is absent. Wait until nursing is complete before considering TB-500.
What is the best peptide stack for women?
The most commonly used women's wellness stack is GHK-Cu (1--2 mg/day for skin and hair) + BPC-157 (250--500 mcg/day for gut and tissue repair) + PT-141 (0.5--1.0 mg as needed for libido). These three cover collagen synthesis, healing signaling, and central arousal with no known adverse interactions between them.
Not medical advice. This guide is for educational and research purposes only. These are research peptides (except PT-141 / Vyleesi, which requires a prescription). Consult a licensed healthcare provider before starting any peptide protocol, especially if pregnant, nursing, or planning pregnancy.
Related
Menopause Peptides
Peptides for perimenopause and beyond
Compare
BPC-157 vs TB-500
Which healing peptide is right for you
Peptide Pulse Newsletter
Get the next guide before everyone else
One email a month. Dosing protocols, new peptide breakdowns, research summaries. Unsubscribe anytime.
© 2024--2026 ASCEND · Calculator · Learn Hub · About · Privacy
For research & educational use only. Not medical advice.
For research & educational use only. Not medical advice.